Personified treatment of patients with irritable bowel syndrome and obesity

Abstract

The purpose of the work. To evaluate the effectiveness of the use of the probiotic Alflorex and mesalazine in complex therapy in patients with irritable bowel syndrome (IBS) with diarrhea and constipation, combined with obesity, with CT and TT genotypes according to the polymorphic variant C-159T of the CD14 gene. Materials and methods. We examined 48 patients with IBS associated with obesity. In the dynamics of treatment with probiotic Alflorex and mesalazine we determined the content in the serum of C-reactive protein (CRP), tumor necrosis factor-α (TNFα), transforming growth factor-β1 (TGFβ1), interleukin-10 (IL-10), 8 - isoprostane, ceruloplasmin (CP), medium molecular weight peptides and calprotectin in feces. The polymorphic variant of the CD 14 gene (C-159T) was analyzed by polymerase chain reaction. The results of the study. The use of Alflorex and mesalazine in the complex therapy for patients with IBS with diarrhea, combined with obesity, leads to normalization of the IL-10, TGFβ1, medium molecules and a decrease in TNFα (by 37.0%), CRP (1.7 times), 8-isoprostane (by 35.8%), CP (by 44.4%), calprotectin content (by 41.1%). While predominance of constipation in the dynamics of treatment it was showed normalization of IL-10, TGFβ1, medium molecules, CRP, 8-isoprostane, CP, calprotectin and a decrease in TNFα (1.9 times). Conclusions. Probiotic and mesalazine therapy for a month leads to a significant increase in the effectiveness of treatment of patients with IBS with concomitant obesity in the presence of CT and TT genotypes of the polymorphic variant of the CD 14 gene (C-159T) with a predominance of both diarrhea and constipation.